206989-61-9 Usage
Description
4-ACETYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER, also known as tert-Butyl 4-Acetylpiperidine-1-carboxylate, is a light yellow oil that serves as a valuable research chemical. It is an organic compound with a complex molecular structure, which makes it a significant compound for scientific investigations and pharmaceutical research.
Uses
Used in Pharmaceutical Research:
4-ACETYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a research chemical for the development of novel pharmaceuticals. Its unique structure and properties make it a promising candidate for the synthesis of new drugs and the study of various biological activities.
Used in Chemical Synthesis:
In the chemical industry, 4-ACETYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a key intermediate in the synthesis of various organic compounds. Its versatile structure allows for further functionalization and modification, leading to the creation of a wide range of chemical products.
Used in Analytical Chemistry:
4-ACETYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is employed as a reference compound in analytical chemistry. Its distinct properties make it useful for the calibration of analytical instruments and the development of new analytical methods.
Used in Material Science:
In the field of material science, 4-ACETYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a component in the development of new materials with specific properties. Its unique molecular structure can contribute to the creation of materials with enhanced performance characteristics.
Overall, 4-ACETYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is a versatile compound with a wide range of applications across various industries, including pharmaceutical research, chemical synthesis, analytical chemistry, and material science. Its unique properties and potential for further development make it an essential tool in the ongoing pursuit of scientific knowledge and technological advancements.
Check Digit Verification of cas no
The CAS Registry Mumber 206989-61-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,6,9,8 and 9 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 206989-61:
(8*2)+(7*0)+(6*6)+(5*9)+(4*8)+(3*9)+(2*6)+(1*1)=169
169 % 10 = 9
So 206989-61-9 is a valid CAS Registry Number.
InChI:InChI=1/C12H21NO3/c1-9(14)10-5-7-13(8-6-10)11(15)16-12(2,3)4/h10H,5-8H2,1-4H3
206989-61-9Relevant articles and documents
Meso-piperidine calix[4]pyrrole: Synthesis, structure and ion binding studies
He, Ying-Chun,Pan, Ji-Gang
, p. 8208 - 8212 (2015)
We report the synthesis, structure and preliminary solution phase ion binding properties of the calix[4]pyrrole 3a-c. Calix[4]pyrrole 3a and 3b, the first to be prepared via one-pot reaction, were obtained by reacting the ketone 7 with pyrrole in the presence of an acid catalyst. On the basis of 1H NMR spectroscopic analyses and the titrations of UV spectrophotometry, it was concluded that compound 3a possesses significantly enhanced selectivity for fluoride anion in chloroform, and formes 1:1 (ligand: anion) complexes with fluoride and chloride anions.
TRPML MODULATORS
-
, (2021/06/26)
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
TREATMENT OF INDOLENT OR AGGRESSIVE B-CELL LYMPHOMAS USING A COMBINATION COMPRISING BTK INHIBITORS
-
, (2019/06/17)
Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody. The potent and selective BTK inhibitor in combination with the anti-PD-1 antibody have a manageable toxicity profile in patients with indolent and aggressive lymphomas.